Ozempic vs. Wegovy vs. Generic Semaglutide: What's Available in Canada

If you have started looking into medical weight management, you have probably noticed the same active ingredient — semaglutide — appearing under several different names: Ozempic, Wegovy, and now a growing list of generics. It's confusing, and the confusion matters, because these products are authorized for different uses in Canada even though they share the same molecule.

This guide breaks down what each one is, how they differ in dose and approved use, how the new generics fit in, and what all of this means when you talk to a licensed healthcare provider.

This article is educational and is not a substitute for medical advice. Semaglutide is a prescription medication, and eligibility is determined through a medical consultation.

They're the same molecule — but not the same product

Ozempic, Wegovy, and generic semaglutide all contain the same active ingredient: semaglutide, a GLP-1 receptor agonist that mimics a natural gut hormone to reduce appetite and support fullness.

From a purely molecular standpoint, the semaglutide in each is the same. What differs is the dose, the Health Canada–authorized use, the injector device, and the price. This is the single most misunderstood part of the conversation: same ingredient does not mean same approved use.

Ozempic

Ozempic is Novo Nordisk's once-weekly semaglutide injection. Health Canada authorized it in 2018 for adults with type 2 diabetes, to improve blood sugar control alongside diet and exercise. It is available in doses up to 2 mg weekly.

Ozempic is not authorized by Health Canada specifically for weight management. It is, however, sometimes prescribed off-label for that purpose at a clinician's discretion when clinical criteria are met. Off-label prescribing is legal and common in Canada, but it's a decision made between you and your provider — not a Health Canada–approved indication.

Wegovy

Wegovy is also semaglutide, made by the same manufacturer, but it is dosed higher — up to 2.4 mg weekly — and it is the version Health Canada authorized specifically for chronic weight management.

Health Canada approved Wegovy in 2021 for adults with:

• a BMI of 30 kg/m² or greater (obesity), or

• a BMI of 27 kg/m² or greater (overweight) with at least one weight-related health condition, such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea.

Because Wegovy was designed, dosed, and studied for weight management, it is the semaglutide product most directly indicated for that purpose in Canada. Its approval was based on the STEP clinical trial program; in the STEP 1 trial, participants lost an average of 14.9% of their body weight over 68 weeks alongside lifestyle changes.

Generic semaglutide

In 2026, Health Canada began authorizing generic versions of semaglutide. A Health Canada–authorized generic contains the same active ingredient, at the same strength, in a comparable form to the brand-name product, and must meet Health Canada's standards for safety, efficacy, and quality before it can be sold.

A few things are worth understanding:

• A generic is approved for a specific indication, just like a brand. The first generics authorized in Canada were reviewed against particular reference products and uses — so "generic semaglutide" is not automatically interchangeable for every purpose. Your provider and pharmacist will confirm what any given generic is authorized for.

• Minor differences can exist. The injector device, inactive ingredients (buffers, preservatives), and manufacturer may differ from the brand. The active molecule is the same.

• The main advantage is cost. Generics have expanded lower-cost access to semaglutide for Canadians, which had been one of the biggest barriers to starting and staying on treatment.

Quick comparison

Note: "off-label" use of a product for a purpose Health Canada hasn't authorized is a clinical decision made with your provider. Always confirm the current, authorized indication and dose with your provider and pharmacist, and review the product monograph.

What about compounded semaglutide?

You may see compounded semaglutide advertised, particularly from sources outside Canada. It's important to know that Health Canada does not permit compounded versions of semaglutide the way some other countries do. Reputable Canadian providers dispense only Health Canada–authorized semaglutide products. If a source offers compounded semaglutide, that's a signal to be cautious and to speak with a licensed Canadian provider.

Which one is right for you?

That's not a question to answer from an article — it depends on your health history, your goals, what you're being treated for, coverage, and cost. A licensed healthcare provider will weigh the approved indications, the appropriate dose, and your individual circumstances to determine what, if anything, is suitable for you.

The practical takeaway: Ozempic and Wegovy are the same molecule at different doses and for different authorized uses, generics have made semaglutide more affordable, and compounded versions aren't authorized in Canada. A medical consultation is how you sort out which pathway fits.

At Kinro, your consultation, your prescription if you're eligible, and ongoing clinical support are coordinated through our own pharmacy — so if a generic or brand-name product is appropriate for you, dispensing and follow-up stay connected in one place.

Start your Consultation